Research Memo: Loss of Subsidized Drug Coverage and Mortality Following Medicaid Disenrollment: Translating our Findings and Implications for Medicaid Policy
Presented to Congressional Committee Staff
In Their Own Words
This Doctor Spends Hours Talking to Insurers. Her Patients Suffer The Most.
Prior Authorizations Were Meant to Cut Costs. Now They Delay Care, Says CHOP Rheumatologist
Print:
The following excerpt is from an op-ed that first appeared in the Philadelphia Inquirer on February 28th, 2024.
My patient — we’ll call her Sydney — was a young teenager who had been sick for weeks. We ultimately diagnosed her with an aggressive, rare disorder of the blood vessels that can restrict blood flow and damage vital organs.
Sydney received Remicade, a targeted, immunosuppressive medication known as a biologic during her hospitalization, and it worked. Her fevers abated, her energy returned, and her labs showed dramatic improvement. Yet, despite Sydney’s visible improvement during her hospital stay, her insurance provider denied payment for her Remicade treatments when she went home.
After an initial letter explaining the necessity of her medication, followed by a 75-minute phone call with Sydney’s insurance company three weeks later, we ultimately got her medication approved, four weeks after we prescribed it. Fortunately, Sydney was only one day late for her monthly dose.
Unfortunately, I have many other patients whose struggles with insurance over medication coverage haven’t ended so well.
As a pediatric rheumatologist, I care for children with rare forms of chronic illness for which we now have highly effective therapies. But too often, my patients can’t access these effective therapies because insurers put up many barriers to coverage.
Read the entire op-ed here.
Author
Dori Abel, MD
Fellow, Pediatric Rheumatology, Children’s Hospital of Philadelphia
More on Health Care Access & Coverage
Medicare’s New Drug Spending Cap Will Likely Help Few Seniors
Many With High Drug Costs Have Supplemental Coverage and Won’t Reach the $2,000 Out-of-Pocket Cap, a New LDI Study Finds
How State Medicaid Choices Eased Children’s Coverage Loss After COVID-19
New Research Shows That Continuous Eligibility and Streamlined CHIP Structures Helped Protect Kids During the “Unwinding”
Medicaid Cuts Will Imperil Many Sick Recipients
Those on Medicaid and Medicare Will Die at Higher Rates If They Lose Low-Cost Drug Coverage, New LDI Study Shows
Six Policy Actions to Help Medicare-Medicaid Enrollees Get Better Care
LDI Fellows Outline a Path Forward Based on Lessons From the Last Decade
Medicaid’s Low Pay for Doctors Makes it Hard For Patients to Find Care
Paying More For Primary Care Showed Dramatic Results, LDI Fellow Found